PRAXPraxis Precision Medicines Inc

Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger seizure reduction.read more...

Praxis’s vormatrigine candidate failed to reduce the monthly frequency of focal onset seizures in certain patients in a trial.

Moody Aldrich Partners LLC bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 41,731 shares of the company's stock, valued a...

Pictet Asset Management Holding SA bought a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 240,588 shares of the company's stock, valued at ap...

M&T Bank Corp purchased a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,586 shares of the company's stock, valued at approximately...

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 37,377 sha...

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) have been assigned an average rating of "Buy" from the twenty analysts that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has iss...

Praxis Precision Medicines (NASDAQ:PRAX) will be releasing its Q1 2026 earnings before the market opens on Friday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-1-praxis-precision-medicines-inc-stock...

Massachusetts Financial Services Co. MA purchased a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the 4th quarter, according to its most recent 13F filing with the...